Xellia expands global specialty anti-infective manufacturing

11 October 2017
drugs_pills_tablets_big

Denmark-based Xellia Pharmaceuticals, a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, has held an official ground breaking ceremony for a new $25 million expansion at its Copenhagen site.

This site houses Xellia’s headquarters and is the company’s largest product manufacturing plant. Since 2013, Xellia is a wholly-owned by Novo Holdings A/S, which is also a major shareholder in Danish diabetes care giant Novo Nordisk (NOV: N).

Xellia’s Copenhagen site is responsible for manufacturing, stability testing and packaging of both sterile active pharmaceutical ingredients (APIs) and the finished dosage forms (FDFs) for anti-infectives such as vancomycin, and colistimethate sodium.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics